** Shares of drugmaker Gilead GILD.O rise 5% to $123.58

** RBC Capital Markets estimates GILD's HIV prevention drug Yeztugo could beat consensus expectations in Q3, projecting sales of $45 million compared to the Street's $35 million, driven by switching demand and early uptake

** CVS's decision not to cover Yeztugo yet, along with formulary delays and continued use of generic Truvada, may limit near-term uptake, brokerage adds

** RBC Capital Markets expects a Q3 beat for GILD's HIV drug Biktarvy, but continues to monitor for any potential MFN impact longer term

** Company is expected to report Q3 earnings on October 30

** Including session moves, stock up 33.98% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))